Enliven Therapeutics Stock Forecast

Buy candidate since Jun 17, 2026 Gain 9.50%

The Enliven Therapeutics, Inc. stock price gained 2.83% on the last trading day (Thursday, 25th Jun 2026), rising from $47.77 to $49.12. During the last trading day the stock fluctuated 7.13% from a day low at $47.19 to a day high of $50.56. The price has risen in 8 of the last 10 days and is up by 32.76% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 546 thousand more shares were traded than the day before. In total, 3 million shares were bought and sold for approximately $135.64 million.

The stock has broken the very wide and horizontal trend up. Breaks like this are often followed by swift and strong movements, and any correction down to the breakline at approximately. $48.04 is considered to be a "second chance" to hit a potential runner. It is, however, important that volume does follow the price as false breaks may appear and it may move back into the horizontal trend. Based on the rectangle-formation theory the stock is predicted to reach $62.48 sometime during the next 3 months.

ELVN Signals & Forecast

Mostly positive signals in the chart today. The Enliven Therapeutics, Inc. stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at $46.28 and $41.16. A breakdown below any of these levels will issue sell signals. A buy signal was issued from a pivot bottom point on Monday, June 08, 2026, and so far it has risen 46.06%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume is rising along with the price. This is considered to be a good technical signal.

Support, Risk & Stop-loss for Enliven Therapeutics, Inc. stock

On the downside, the stock finds support just below today's level from accumulated volume at $46.13 and $42.55. There is a natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Enliven Therapeutics, Inc. finds support just below today's level at $46.13. If this is broken, then the next support from accumulated volume will be at $42.55 and $40.36.

This stock may move very much during the day (volatility) and with a very large prediction interval from the Bollinger Band this stock is considered to be "very high risk". During the last day, the stock moved $3.37 between high and low, or 7.13%. For the last week, the stock has had daily average volatility of 6.53%.

The Enliven Therapeutics, Inc. stock is extremely overbought on RSI14 (76). Normally this may pose a good selling opportunity but since the stock has broken the trend up, the chance for a major correction due to high RSI is very small as the stock will find support at the trend broken.

Our recommended stop-loss: $47.41 (-3.48%) (This stock has very high daily movements and this gives very high risk. The RSI14 is 76 and this increases the risk substantially. There is a buy signal from a pivot bottom found 12 days ago.)

Trading Expectations (ELVN) For The Upcoming Trading Day Of Friday 26th

For the upcoming trading day on Friday, 26th we expect Enliven Therapeutics, Inc. to open at $48.96, and during the day (based on 14 day Average True Range), to move between $47.55 and $50.69, which gives a possible trading interval of +/-$3.14 (+/-6.60%) up or down from last closing price. If Enliven Therapeutics, Inc. takes out the full calculated possible swing range there will be an estimated 6.60% move between the lowest and the highest trading price during the day.

With no resistance above and support from accumulated volume @ $46.13, some $2.99 (6.09%) from the current price of $49.12, our system finds the risk reward attractive.

Is Enliven Therapeutics, Inc. stock A Buy?

Enliven Therapeutics, Inc. holds several positive signals and has broken the very wide and horizontal trend up. As the stock is in great technical shape we, therefore, consider it to be a good choice at these current levels and we are expecting further gains during the next 3 months. We have upgraded our analysis conclusion for this stock since the last evaluation from a Buy to a Strong Buy candidate.

Current score: 6.027 Strong Buy Candidate Upgraded

Predicted Fair Opening Price

Predicted fair opening price on June 26, 2026 - $48.96 ( 0.336%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker*
*Your capital is at risk